Doxorubicin Hydrochloride Liposome and Bortezomib in Treating Patients With Refractory Hematologic Cancer or Malignant Solid Tumor or Metastatic Breast Cancer

NCT00237627 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

107

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer
Leukemia
Lymphoma
Multiple Myeloma and Plasma Cell Neoplasm
Ovarian Cancer
Unspecified Adult Solid Tumor, Protocol Specific

Interventions

DRUG: PS-341
DRUG: Doxil
DRUG: Velcade

Sponsor

UNC Lineberger Comprehensive Cancer Center

Collaborators

[object Object]